| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4277130 | Urology Practice | 2014 | 5 Pages |
Abstract
Although there is insufficient proof of improved health outcomes, expert opinions and Food and Drug Administration approval suggest a potential benefit of PCA3 use before considering repeat biopsy because the risk of undetected, clinically significant prostate cancer is low in cases of a low PCA3 score. Given that PCA3 may lead to a significant decrease in unnecessary biopsies, the cost-benefit balance of introducing PCA3 needs further assessment based on strict methodology incorporating health care outcomes.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Guillaume Ploussard, Alexandre de la Taille,